Research Interest: Nanomedicine
Name | PhD Program | Research Interest | Publications |
---|---|---|
Benhabbour, Rahima WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
Dr. Benhabbour’s academic research focuses on development of novel tunable delivery platforms and polymer-based devices to treat or prevent a disease. Her work combines the elegance of organic and polymer chemistry with the versatility of engineering and formulation development to design and fabricate efficient and translatable nanocarriers and drug delivery systems for cancer treatment and HIV prevention. Dr. Benhabbour has also Founded her startup company Anelleo, Inc. (AnelleO) in 2016 to develop the first 3D printed intravaginal ring as a platform technology for women’s health. Current technologies in development in Dr. Benhabbour’s Lab include: |
Li, Zibo WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
My research has focused on developing new radio-chemistry, imaging probes, and therapeutic approaches including nanomedicine for various diseases. Most importantly, we have the culture of forming an active collaboration with people in different field. With a cGMP lab located within our facility, we are also experienced on developing lead agents and translate it to clinic. |
Rizvi, Imran WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
Dr. Rizvi’s expertise is in imaging and therapeutic applications of light, bioengineered 3D models and animal models for cancer, and targeted drug delivery for inhibition of molecular survival pathways in tumors. His K99/R00 (NCI) develops photodynamic therapy (PDT)-based combinations against molecular pathways that are altered by fluid stress in ovarian cancer. He has co-authored 46 peer-reviewed publications and 5 book chapters with a focus on PDT, biomedical optics, and molecular targeting in cancer. |
Button, Brian WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
The Button lab in the Department of Biochemistry and Biophysics is part of the Marsico Lung Institute. Our lab is actively involved in projects that are designed to define the pathogenesis of muco-obstructive pulmonary disorders and to identify therapies that could be used to improve the quality of life in persons afflicted by these diseases. In particular, our research works to understand the biochemical and biophysical properties of mucin biopolymers, which give airway mucus its characteristic gel-like properties, and how they are altered in diseases such as Asthma, COPD, and cystic fibrosis. |
Knight, Abigail WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
The Knight group focuses on designing novel macromolecular materials with functions inspired by biological systems. These materials will generate platforms of new biomimetic polymeric architectures addressing growing concerns in treating, diagnosing, and preventing human disease. This research bridges the fields of chemical biology and polymer chemistry using characterization and synthetic tools including polymer and solid-phase synthesis and nanomaterial characterization. Specific project areas include: (1) developing a new class of peptide-polymer amphiphiles inspired by metalloproteins, (2) designing well-defined polymer bioconjugates for biosensing, and (3) evolving functional biomimetic polymers. |
Anselmo, Aaron C. WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
The human body coexists with communities of microbes and bacteria called microbiota, and the balance of these microbes regulates both health and disease. In some cases, imbalances in microbiota have been linked to diseases, such as cancer and diabetes. My group will develop approaches and formulations to deliver specific compounds and microbes to modulate microbiota composition towards healthy states. Other research interests include the development of cell-mediated delivery systems, synthetic cells and nanoparticle drug-delivery systems for applications in vascular disease and cancer. |
Wang, Andrew Z. WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
My laboratory has two research directions. One is to utilize nanotechnology to develop novel diagnostics and therapeutics to improve cancer treatment. The other is to use techniques developed in tissue engineering to develop in vitro 3D models of cancer metastasis. |
Liu, Rihe WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
The research interests of the Liu Lab are in functional proteomics and biopharmaceuticals. Currently we are working on the following projects: (1). Using systems biology approaches to decipher the signaling pathways mediated by disease-related proteases such as caspases and granzymes and by post-translationally modified histones. We address these problems by performing functional protein selections using mRNA-displayed proteome libraries from human, mouse, Drosophila, and C. elegans. (2). Developing novel protein therapeutics and nucleic acid therapeutics that can be used in tumor diagnosis, treatment, and nanomedicine. We use various amplification-based molecular evolution approaches such as mRNA-display and in vivo SELEX to develop novel single domain antibody mimics on the basis of very stable protein domains or to generate aptamers on the basis of nuclease-resistant nucleic acids, that bind to important biomarkers on the surface of cancer cells. We further conjugate these biomarker-binding affinity reagents to small molecule drugs or nanoparticles for targeted delivery of therapeutic agents. (3). Identifying the protein targets of drugs or drug candidates whose action mechanisms are unknown. We combine molecular proteomic and chemical biology approaches to identify the protein targets of drugs whose target-binding affinities are modest. |
Gershon, Timothy R. WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
As a pediatric neurologist and brain tumor researcher, I seek to understand the link between brain growth and childhood brain tumors. My lab focuses on in vivo studies of the normal process of postnatal neurogenesis and the pathologic process of brain tumor growth, using mice genetically engineered to develop medulloblastoma. Our in vivo approach allows us to study how metabolism, apoptosis regulation and cell cycle control contribute to development and tumor formation. Through a long-term collaboration with Drs. Alexander Kabanov and Marina Sokolsky in the Eshelman School of Pharmacy, we are using insight from tumor biology to develop new, nanoparticle-delivered treatments for medulloblastoma, which we then test in our in vivo models. Most recently, we have used single-cell transcriptomic analysis (scRNA-seq) to understand how these treatments impact brain tumors, growing in vivo. |
DeSimone, Joseph M. WEBSITE PUBLICATIONS |
PHD PROGRAM RESEARCH INTEREST |
The direct fabrication and harvesting of monodisperse, shape-specific nano-biomaterials are presently being designed to reach new understandings and therapies in cancer prevention, diagnosis and treatment. Students interested in a rotation in the DeSimone group should not contact Dr. DeSimone directly. Instead please contact Chris Luft at jluft@email.unc.edu. |